What's Ahead for Rigel Pharma (RIGL): A Look Back at Recent Q&A

Steve Kanaval  |

I was reading the transcript from the March 2016 Earnings call (see below)..and thought it would be a good time to reach out and get some feedback from Raul Rodriguez, Rigel Pharmaceuticals - CEO as to where they are to date. I like the company who works closely with Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies.

" 2016 will be an absolutely pivotal year for Rigel. We will continue managing our resources wisely, and plan to end 2016 with sufficient cash reserves to maintain operations into Q3 of 2017. We will continue our effort to validate the activity of Fostamatinib in treating IgA nephropathy, to set the stage for Rigel, and a new partner, to advance into further clinical trials ".

" By the end of the year, we will have gained insights into Fostamatinib's efficacy in autoimmune hemolytic anemia, and hope to set the stage for a pivotal clinical program, for this indication. Perhaps most significantly, by the end of the year we will have demonstrated Fostamatinib's potential in ITP, and we hope to be at the doorstep of our first NDA filing as a company. This will be a major advance for Rigel, and we look forward to it ."

From previous call from the Q & A with a question from JP Morgan.

" The first one is that, we talked a lot about ITP, but you also mentioned IgA nephropathy readout, maybe just setting the stage for that. As well as, what kind of pre-commercial activities are you doing, just trying to understand the side-scope of the sales force and when we might hear more definitive strategy, there? Will it be post the first readout in ITP, or will you wait for both?"

Raul Rodriguez, Rigel Pharmaceuticals - CEO, President , " In IgA nephropathy, the first cohort of that trial should complete readout very shortly. And we will have those results by the end of the year. It is a 6-month study, so it'll probably be in Q4 of the year, and that will be a direct [Mostho]. Keep in mind, this is at the 100mg BIT dose group, and from this dose group, we are looking for a signal that this product is, one, Safe, and two, Having some type of benefit. "

" So as yet, we're not expecting a strong P-value-type result for IgA nephropathy at this point. But I think it should be sufficient to engage with a potential partner in Asia while we have the next dose group, the 150mg dose group, underway. And we hope to have that trial enrolling, later this year."

" On pre-commercial plans, we are working very hard right now, in drafting pre-commercial plans for Fostamatinib in the US for ITP, and hopefully, subsequent to that, autoimmune hemolytic anemia. And, after some continued iterations of those plans, we plan to share those with you later in the year. The exact timing, I'm not exactly set yet on, but we probably will tell you something close to when we release the first clinical trial results."


Rigel Pharmaceuticals, Inc. (RIGL) is a clinical-stage biotechnology company, engages in the discovery and development of novel and targeted drug candidates in the therapeutic areas of immunology, oncology, and immuno-oncology. It is developing fostamatinib, an oral spleen tyrosine kinase inhibitor, which is in Phase III clinical trials for immune thrombocytopenic purpura and in Phase II clinical trials for autoimmune hemolytic anemia and IgA nephropathy; R348, an ophthalmic janus kinase/spleen tyrosine kinase inhibitor that is in Phase II clinical trials for the treatment of patients with ocular graft-versus-host disease; and two oncology product candidates in Phase I development. The company has license agreements with Aclaris Therapeutics International Limited for the development and commercialization of certain janus kinase inhibitors for the treatment of alopecia areata and other dermatological conditions; AstraZeneca AB for the development and commercialization of R256, an inhaled janus kinase inhibitor; BerGenBio AS for the development and commercialization of an oncology program; and with Daiichi Sankyo to pursue research related to a specific target from a novel class of drug targets called ligases, as well as a collaboration agreement with Bristol-Myers Squibb Company for the discovery, development, and commercialization of cancer immunotherapies. Rigel Pharmaceuticals, Inc. was founded in 1996 and is based in South San Francisco, California.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of equities.com. Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to: http://www.equities.com/disclaimer.

Companies

Symbol Name Price Change % Volume
RIGL Rigel Pharmaceuticals Inc. 2.04 -0.10 -4.67 1,400,202 Trade

Comments

Watchlist

Symbol Last Price Change % Change
AAPL

     
AMZN

     
HD

     
JPM

     
IBM

     
BA

     
WMT

     
DIS

     
GOOG

     
XOM

     
BRK.A

     
FB

     
JNJ

     
WFC

     
T

     
NFLX

     
TSLA

     
V

     
UNH

     
PG

     

Blockchain in Fintech - Discussion at the EU Parliament

From the recent Blockchain For Europe Summit in Brussels: Panel on Financial Market Infrastructure